Growth Hormone Peptides Ipamorelin and Sermorelin Draw Increased Research Interest in Longevity Medicine

Ipamorelin is a synthetic pentapeptide that selectively activates the ghrelin receptor to stimulate pulsatile growth hormone release from the anterior pituitary. What distinguishes it from other GHRPs is its remarkably clean side-effect profile: at therapeutic doses, ipamorelin does not measurably elevate cortisol, prolactin, ACTH, or aldosterone � hormones that many competing secretagogues raise to clinically relevant levels. This selectivity makes ipamorelin a favored subject for longer-duration protocols examining body composition changes, fat metabolism, and sleep quality improvements.

Sermorelin, a truncated 29-amino-acid analog of endogenous growth hormone releasing hormone (GHRH), works upstream of ipamorelin by stimulating the pituitarys own synthesis and release machinery. Because it preserves the natural GH pulsatility and feedback loop, sermorelin is considered one of the more physiologically authentic approaches to GH support � a characteristic that anti-aging clinicians value when seeking sustainable, long-term protocols for patients. Combination approaches pairing sermorelin or CJC-1295 with ipamorelin have emerged as a common protocol design in longevity research settings.

Both peptides face a shared regulatory constraint: they remain non-FDA-approved research compounds for standalone therapeutic use, and pending the outcome of the anticipated FDA Category 2 reclassification, access through compounding pharmacies could broaden significantly in 2026. Academic interest has also grown in studying GH secretagogues in the context of hypogonadism and age-related sarcopenia, where optimizing GH and IGF-1 levels may complement hormone replacement strategies without the risks associated with exogenous growth hormone administration.